寻求合作
[供] 德国大学提供肾癌诊断和分化的术前标志物
合作类型:技术     行业类别: 水产养殖和渔业     国家:德国
发布时间:2018年06月14日     过期时间:2021年03月10日     点击数:16

德国的一所大学开发了一种无创诊断和鉴别良性和恶性肾癌的标记。该明确区分将改进适当治疗的计划。该大学提供许可协议。

A German university has developed a marker for non-invasive diagnosis and differentiation of benign and malignant renal carcinoma. An unequivocal differentiation will improve the planning of the adequate treatment. The university offers a license agreement.

 

Description     

Kidney cancer is classified as malignant tumors originating from different renal cells with several subtypes. The cells of these subtypes can mimic a benign kidney tumor, called oncocytomas. The unequivocal differentiation is essential for planning the adequate operative procedure and the patient follow-up monitoring (which is not necessary for oncocytomas). To date, it is not possible to reliably differentiate between malignant subtypes and benign kidney tumors by means of the available antibody panel and imaging methods.

 

A German university found a splice isoform of Vimentin, namely Vimentin3 (Vim3), as an indicator of benign oncocytomas. Renal cell carcinomas (RCCs) are negative for Vim3. They also discovered a truncated variant of the protein MAPK p38, namely Mxi-2, which indicates RCC, including all subtypes. Oncocytomas, however, is negative for Mxi-2. Both markers are detectable by means of monoclonal antibodies directed against Vim3 and Mxi-2 in body fluids, such as urine, as well as in tissue.

 

Detection of both markers in urine makes it possible for the first time to provide urologists and oncologists with a non-invasive test for a pre-operative diagnosis so as to appropriately treat the patient and plan the follow-up.

 

The marker is also usable for routine medical check-ups (for persons aged 55 and above).

 

The university offers a license agreement to companies from the diagnostic industry. The partner should cooperate to further develop the prototype to a final product.

 

 

Type and Role of Partner Sought    

The university offers a license agreement

 

Potential licensees come from the diagnostic industry. Especially those companies that offer immunohistochemical analyses and investigations in body fluids (by means of antibody detection) are addressed, specifically urine diagnostics.

 

The cooperation would include the further development to a ready to use product. This involves the relevant studies. Meanwhile the prototype is under development (test strip and ELISA test).

【供】180123 TODE20180309001
回复列表
1 / 共0页


发表回复:
请在下面登录后,才能发表回复
会员帐号: 密码: